Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
Background: Immune checkpoint inhibitors (ICIs) have become an effective treatment option for cancer. KRAS, EGFR and TP53 are common mutated oncogenes in cancer whose single gene status may predict the therapeutic effect of clinical ICIs. In this efficacy evaluation, we aimed to clarify whether the...
Saved in:
Main Authors: | Shui Liu (Author), Shuai Geng (Author), Ning Shi (Author), Lili Zhang (Author), Wenxin Xue (Author), Yiwen Li (Author), Kai Jiang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
by: Pinaki Mondal, et al.
Published: (2023) -
Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report
by: Cheng Fang, et al.
Published: (2019) -
Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
by: Wenbo Qi, et al.
Published: (2023) -
Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer
by: Hye Jung Hwang, et al.
Published: (2020) -
Somatic intronic TP53 c.375+5G mutations are a recurrent but under‐recognized mode of TP53 inactivation
by: M Herman Chui, et al.
Published: (2022)